San Diego, CA (PressExposure) September 20, 2012 -- Marcie Glicksman, Senior Director of the Leads Discovery Group of LDDN at Harvard University will give a presentation on "Strategies for Discovery of Kinase Inhibitors for Neurodegenerative Diseases" at the Protein Kinases and Drug Design conference taking place on Nov 8-9, 2012 in Boston, MA.
Neurodegenerative diseases are challenging from a drug discovery perspective with virtually no disease modifying agents available on the market. The Laboratory for Drug Discovery at the Harvard NeuroDiscovery Center works with academic labs around the country in a collaborative model of drug discovery within academics. The LDDN was established in 2001 as a model for how academic research can be applied to drug discovery. The LDDN has an established track record of progressing projects along the drug discovery pathway, from assay development and high-throughput screening through medicinal chemistry on lead compounds to testing candidate drugs in animal models of disease. Kinase targets are attractive drug discovery targets and there have been a number of successes in oncology, but what are the challenges of kinase targets for neurodegenerative diseases? In her presentation, Dr. Glicksman will describe some of the challenges and promise of kinase inhibitors for neurodegenerative diseases.
Dr. Marcie Glicksman has extensive experience in assay development, high throughput screening, and chemical databases, as well as animal pharmacology and preclinical development. She has been in the field of drug discovery for twenty years, the most recent seven years in academics and thirteen years in the pharmaceutical /biotech industry. Before joining LDDN, she was at the start-up company, Descartes Therapeutics. Before this, she was Director of Leads Discovery at Cubist leading a group in the development of antibiotics with a structure-based drug design approach. Before Cubist, she was in Leads Discovery at DuPont-Merck (later DuPont Pharmaceuticals) and Cell Biology at Cephalon, Inc. She led the assay development and screening programs for many cell-based assays including a protease project and numerous G-protein coupled receptor projects.
She also led a program for Alzheimer's and Parkinson's disease that resulted in co-inventorship of CEP1347, a drug candidate directed at a kinase in Phase 3 clinical trials. She was elected in 2005 to the Board of Directors of the Society for Biomolecular Sciences and served as its Chairman for two years. She is on the science advisory board for the Alzheimer's disease foundation (ADDF/ISOA) and the California Institute for Regenerative Medicine (CIRM). She also reviews grants for NIH, the Michael J Fox, Alzheimer's Association, and Rett Foundations. Dr. Glicksman regularly consults, which includes filing an Investigational New Drug application with the FDA, as well as projects leading to the development of new technologies.
GTC's Protein Kinases and Drug Design conference, one of two parallel tracks of the Cancer Summit - Novel Approaches to Drug Discovery on November 8-9 in Boston, MA, brings together leading experts from the industry and academia to collaborate on the latest cutting edge research on drug design and development, selective and non-selective kinases inhibitors, hit and target identification, oncology kinases and inhibitors, and other kinases targets. Experts will also share their positive and negative experiences on how predictive preclinical models are with clinical efficacy and toxicology.
For more information, please visit http://www.gtcbio.com